Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Vergnenegre

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Revue Des Maladies Respiratoires|April 2, 2002
[Value of 18FDG-CDET in the evaluation of operable bronchial cancer]B Melloni, J Monteil, F Bertin, et al.
British Journal of Cancer|September 22, 2011
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)H LeCaer, F Barlesi, R Corre, et al.
Current Oncology (Toronto, Ont.)|November 23, 2018
Patients with non-small-cell lung cancer harbouring a <i>BRAF</i> mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14J B Auliac, S Bayle, A Vergnenegre, et al.
Revue Des Maladies Respiratoires|January 1, 1993
[Combination of cisplatin-mitomycin-vindesine for inoperable, non-small-cell bronchial cancers. French study group in pneumo-cancerology]J P Kleisbauer, P Thomas, M Perol, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2005
Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie)P Thomas, G Robinet, S Gouva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2013
Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 studyJ Le Treut, M C Sault, H Lena, et al.
BMC Cancer|November 8, 2015
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)C Raynaud, L Greillier, J Mazieres, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancerE Quoix, B Lebeau, A Depierre, et al.
Lung Cancer (Amsterdam, Netherlands)|August 2, 2014
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 studyJ B Auliac, C Chouaid, L Greillier, et al.
Targeted Oncology|August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 StudyJ B Auliac, C Fournier, C Audigier Valette, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Revue Des Maladies Respiratoires|April 2, 2002
[Value of 18FDG-CDET in the evaluation of operable bronchial cancer]B Melloni, J Monteil, F Bertin, et al.
British Journal of Cancer|September 22, 2011
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)H LeCaer, F Barlesi, R Corre, et al.
Current Oncology (Toronto, Ont.)|November 23, 2018
Patients with non-small-cell lung cancer harbouring a <i>BRAF</i> mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14J B Auliac, S Bayle, A Vergnenegre, et al.
Revue Des Maladies Respiratoires|January 1, 1993
[Combination of cisplatin-mitomycin-vindesine for inoperable, non-small-cell bronchial cancers. French study group in pneumo-cancerology]J P Kleisbauer, P Thomas, M Perol, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2005
Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie)P Thomas, G Robinet, S Gouva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2013
Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 studyJ Le Treut, M C Sault, H Lena, et al.
BMC Cancer|November 8, 2015
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)C Raynaud, L Greillier, J Mazieres, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancerE Quoix, B Lebeau, A Depierre, et al.
Lung Cancer (Amsterdam, Netherlands)|August 2, 2014
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 studyJ B Auliac, C Chouaid, L Greillier, et al.
Targeted Oncology|August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 StudyJ B Auliac, C Fournier, C Audigier Valette, et al.
Pageof 5